PLAU and systemic sclerosis: Taken together, our findings suggest that E4 is a promising therapeutic agent for SSc and other fibrosing diseases that exhibit an imbalance of uPA–PAI-1, and its efficacy is likely due to its ability to activate antifibrotic pathways and suppress profibrotic mechanisms, thus regulating multiple key effectors in fibrosis.